Stem Cells http://www.epitomics.com
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

First published online May 4, 2006
Stem Cells Vol. 24 No. 8 August 2006, pp. 1879 -1891
doi:10.1634/stemcells.2005-0564; www.StemCells.com
© 2006 AlphaMed Press

This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
2005-0564v1
24/8/1879    most recent
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Reprints/Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Chan, J.
Right arrow Articles by Fisk, N. M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Chan, J.
Right arrow Articles by Fisk, N. M.

TISSUE-SPECIFIC STEM CELLS

Galectin-1 Induces Skeletal Muscle Differentiation in Human Fetal Mesenchymal Stem Cells and Increases Muscle Regeneration

Jerry Chana, Keelin O’Donoghuea, Manuela Gavinae, Yvan Torrentee, Nigel Kenneaa, Huseyin Mehmeta, Helen Stewartc, Diana J. Wattc, Jennifer E. Morganb,d, Nicholas M. Fiska

aInstitute of Reproductive and Developmental Biology,
bDepartment of Paediatrics, Imperial College London, Hammersmith Campus, London, United Kingdom;
cDepartment of Anatomy, Brighton and Sussex Medical School, Falmer, Brighton, East Sussex, United Kingdom;
dMuscle Cell Biology, Medical Research Council Clinical Sciences Centre, Imperial College London, London, United Kingdom;
eFondazione Istituto di Ricovero e Cura a Carattere Scientifico Ospedale Maggiore Policlinico, Department of Neurological Sciences, Stem Cell Laboratory, University of Milan, Italy

Key Words. Mesenchymal stem cells • scid/mdx • Muscle differentiation • Galectin-1 • Fetal stem cells • Fetal • Myogenesis

Correspondence: Dr. Jerry Chan, MBB.Ch. MRCOG, Department of Obstetrics and Gynaecology, Yong Loo Lin School of Medicine, National University of Singapore & National University Hospital, 5 Lower Kent Ridge Road, Singapore 119074. Telephone: +65-6772-4268; Fax: +65-6779-4753; e-mail: jerrychan{at}nus.edu.sg

Received November 14, 2005; accepted for publication April 28, 2006.
First published online in STEM CELLS EXPRESS   May 4, 2006.


   ABSTRACT
Top
 Abstract
Introduction
 Materials and Methods
 Results
 Discussion
 Disclosures
 Acknowledgments
 References
 
Cell therapy for degenerative muscle diseases such as the muscular dystrophies requires a source of cells with the capacity to participate in the formation of new muscle fibers. We investigated the myogenic potential of human fetal mesenchymal stem cells (hfMSCs) using a variety of stimuli. The use of 5-azacytidine or steroids did not produce skeletal muscle differentiation, whereas myoblast-conditioned medium resulted in only 1%–2% of hfMSCs undergoing muscle differentiation. However, in the presence of galectin-1, 66.1% ± 5.7% of hfMSCs, but not adult bone marrow-derived mesenchymal stem cells, assumed a muscle phenotype, forming long, multinucleated fibers expressing both desmin and sarcomeric myosin via activation of muscle regulatory factors. Continuous exposure to galectin-1 resulted in more efficient muscle differentiation than pulsed exposure (62.3% vs. 39.1%; p < .001). When transplanted into regenerating murine muscle, galectin-1-exposed hfMSCs formed fourfold more human muscle fibers than nonstimulated hfMSCs (p = .008), with similar results obtained in a scid/mdx dystrophic mouse model. These data suggest that hfMSCs readily undergo muscle differentiation in response to galectin-1 through a stepwise progression similar to that which occurs during embryonic myogenesis. The high degree of myogenic conversion achieved by this method has relevance for the development of therapies for muscular dystrophies.


   INTRODUCTION
Top
 Abstract
 Introduction
Materials and Methods
 Results
 Discussion
 Disclosures
 Acknowledgments
 References
 
Skeletal muscle satellite cells have long been considered the only source of stem cells for postnatal muscle regeneration [1, 2]. However, recent reports of muscle formation from bone marrow-derived cells [3–5] in mouse models suggested that bone marrow may also be an important source of stem cells for therapy of muscular dystrophies. Although the cell type derived from bone marrow (BM) in these studies was not characterized, several lines of evidence suggest that they may be mesenchymal stem cells (MSCs). First, after separating BM cells, transplantation of the adherent fraction into regenerating muscle resulted in higher engraftment than with the nonadherent fraction, the former containing MSCs and the latter hemopoietic stem cells (HSCs) [4]. Next, expression of the protein dystrophin was higher following implantation into dystrophin-null muscle of nonpurified BM compared with marrow enriched for HSCs and thus depleted of MSCs [3]. More recently, Shi et al. demonstrated that the MSCs and not the hemopoietic compartment in human BM is the predominant cell population capable of fusing with myoblasts [6]. Finally, other groups have confirmed myogenic differentiation after MSC transplantation into regenerating muscle [7, 8].

The identification of human fetal MSCs (hfMSCs) [9, 10] raises the possibility of using these cells to repopulate diseased or traumatized muscle. We [9] have reported that hfMSCs can be readily isolated in first trimester fetal blood, liver, and BM. These cells self-renew extensively and differentiate into multiple mesenchymal lineages [9, 11], as well as nonmesenchymal lineages such as neurons and oligodendrocytes [12]. hfMSCs are readily transducible with integrating vectors without affecting expansion and differentiation capabilities and are thus promising vehicles for autologous ex vivo gene therapy [11]. Autologous use of hfMSCs may now be possible, as ultrasound-guided techniques have already developed to the extent that fetal blood can be sampled in ongoing pregnancies as early as 12 weeks of gestation with <5% loss rate [13], and advances in imaging and thin-gauge fetoscopy should render hfMSC harvest and intraperitoneal reinfusion feasible in the late first/early second trimester [14, 15]. Intrauterine treatment capitalizes on the immune naïveté of the developing fetus and offers the possibility of treating diseases before pathology manifests [16]. Allogeneic therapy with fetal BM and liver-derived hfMSCs is another promising option, as hfMSCs are HLA-II-negative and inhibit lymphocyte proliferation [10]. Recently, allogeneic hfMSCs have been transplanted in utero in a case of prenatally diagnosed skeletal dysplasia with resultant clinical benefit [17].

We investigated myogenic differentiation of hfMSCs with a view to eventual use as autologous or allogeneic cells for treatment of progressive degenerating muscle disease. We show that hfMSCs undergo activation of myogenic regulatory factors (MRFs), followed by extensive muscle differentiation on exposure to galectin-1 in a manner akin to embryonic myogenesis. In addition, they contribute to muscle regeneration in both a murine muscle-injury model and the dystrophin-negative scid/mdx mice and their contribution to skeletal muscle regeneration is significantly increased after prestimulation with galectin-1 prior to transplantation. Our findings suggest that hfMSCs are a potential cell source for therapy of degenerative muscular disease or traumatic muscle loss.


   MATERIALS AND METHODS
Top
 Abstract
 Introduction
 Materials and Methods
Results
 Discussion
 Disclosures
 Acknowledgments
 References
 
Ethics
Fetal blood and tissue and adult BM collection was approved by the Institutional Ethics Committee in compliance with national guidelines regarding the use of fetal tissue for research [18]. All women gave written informed consent for collection and use of fetal and human tissues. All animal procedures were approved by the local ethical review process in accordance with Home Office Project Licenses in the United Kingdom and Italy.

Samples
First trimester fetal blood was obtained by ultrasound-guided cardiac aspiration between 7 and 13 weeks of gestation before clinically indicated termination of pregnancy. Fetal gestational age was determined by crown-rump length measurement. Following the procedure, fetal BM was collected from long bones. Adult MSCs were collected from BM obtained at clinically indicated sternotomy or thoracotomy.

Fetal blood was plated at 106 nucleated cells per 100-mm dish [9] and cultured in D10 (10% fetal bovine serum [FBS] [Stem Cell Technologies, Vancouver, BC, Canada, http://www.stemcell.com] in Dulbecco’s modified Eagle’s medium [DMEM]-high glucose [Sigma-Aldrich, St. Louis, http://www.sigmaaldrich.com]) supplemented with 2 mM L-glutamine, 50 IU/ml penicillin/streptomycin (Gibco-BRL, Gaithersburg, MD, http://www.gibcobrl.com) at 37°C in 5% CO2. Single-cell suspensions of fetal BM were prepared by flushing long bones with 25-gauge needles into D10 via a 70-µm filter and plating as for fetal blood. After 3 days, nonadherent cells were removed, and the medium was replaced. Cells were trypsinized at subconfluence and used for subsequent experiments. Immunophenotyping was performed at passage 2, and hfMSCs from passage 3–10 (n = 10) were used in experiments (at 15 and 40 population doublings).

Adult BM MSCs (n = 4) were either provided by the Tulane Center for Gene Therapy or obtained by flushing marrow from ribs and cultured as for hfMSC isolation. Immunophenotyping and osteogenic and adipogenic differentiation confirmed MSC properties as previously described [19].

C2C12 cells [20] were used as positive controls for immunocytochemical staining. Terminal differentiation was induced by plating C2C12 cells at 8 x 104 cells per cm2 on 0.1 mg/ml Matrigel (BD Biosciences, San Diego, http://www.bdbiosciences.com) in 5% horse serum (HS) (Sigma-Aldrich) for 4 days.

Adipogenic and Osteogenic Differentiation
For osteogenic differentiation, hfMSCs were plated at 2 x 104 cells per cm2 in fibronectin-coated chamber slides and cultured in osteogenic medium (D10 supplemented with 10 mM ß-glycerophosphate, 0.2 mM ascorbate, and 10–8 M dexamethasone (Sigma-Aldrich) for 14 days with changes of medium every 3–4 days. Evidence of osteogenic differentiation was sought from Von Kossa staining. For adipogenic differentiation, hfMSCs were plated as above and cultured in D10 supplemented with 5 µg/ml insulin, 10–6 M dexamethasone, and 60 µM indomethacin (Sigma-Aldrich) for 4 weeks with changes of medium every 3–4 days. Adipogenic differentiation was evidenced by the appearance of lipid inclusion vacuoles, which take up the neutral oil red O.

In Vitro Muscle Differentiation

5-Azacytidine.   hfMSCs were plated in a variety of densities of 1–4 x 104 cells per cm2 on glass or TPX slides coated with fibronectin, Matrigel, gelatin, or collagen (Stem Cell Technologies). They were then exposed to a variety of concentrations of 5-azacytidine (Sigma-Aldrich; 1–24 µM) for 6–48 hours duration in either 2% FBS or serum-free medium (defined as DMEM with 2 mM L-glutamine, 50 U/ml penicillin, 50 µg/ml streptomycin supplemented with 10 ng/ml platelet-derived growth factor-BB, and epidermal growth factor (Sigma-Aldrich) and ITS-plus (Fisher Scientific International, Hampton, NH, http://www.fisherscientific.com). In some experiments, cells received a further 24-hour exposure to 5-azacytidine 3 days later. Following 5-azacytidine exposure, cells were maintained in serum-free medium for up to 21 days. Adult BM MSCs were used as controls.

Horse Serum, Dexamethasone, and Hydrocortisone.   hfMSCs were plated at 2 x 104 cells per cm2 on fibronectin-coated plates and exposed to 5% HS, 10–7 dexamethasone, and 50 µM hydrocortisone in DMEM with 2 mM L-glutamine, 50 U/ml penicillin, and 50 µg/ml streptomycin (all from Sigma-Aldrich), and medium was changed every 3 days, as described by Zuk et al. [21, 22].

Myoblast-Conditioned Medium.   Conditioned medium was harvested from C2C12 cells, cultured at 106 cells per T-75 flask in heat-inactivated D10 medium. After 3 days of culture, the supernatant was collected and filtered (0.22-µm filter) for subsequent experiments. hfMSCs were plated at 2 x 104 cells per cm2 on fibronectin-coated slides with conditioned medium (5%–50%) and serum-free medium. Medium was changed every 3–4 days, and cells were analyzed for expression of the muscle-specific markers desmin and sarcomeric myosin (MF20) after up to 14 days in culture. Adult BM MSCs served as controls.

Galectin-1-Enriched Medium.   Galectin-1-enriched medium was derived as previously reported. Briefly, COS-1 cells were transfected with a plasmid encoding a cDNA clone of rat galectin-1. Supernatant was collected and filtered before use. The concentration of galectin-1 in the supernatant was approximately 20 µg/ml, estimated by comparing dot blots with known concentrations of recombinant galectin-1 [23]. hfMSCs (n = 6) were plated at 2 x 104 cells per cm2 on fibronectin-coated chamber slides with varying concentrations of galectin-enriched medium (100–1,000 ng/ml galectin-1) in serum-free medium for 12 days. Identical control experiments were undertaken using medium from nontransfected COS-1 cells. Adult BM-derived MSCs were also plated under similar conditions and exposed to galectin-1.

Evidence of myogenic differentiation was sought by morphological criteria and immunostaining for desmin and sarcomeric myosin at days 0, 3, 6, 9, and 12. Myogenic conversion was assessed by counting the number of cells positive for desmin and MF20 in six randomly encountered low-powered fields (237–654 cells per field). Pax7, MyoD, and Myogenin expression was similarly assessed using immunocytochemical staining.

In Vivo Muscle Differentiation

c–/{gamma}–/RAG2– Mice.   Two immunodeficient mouse strains were used to investigate in vivo myogenesis. The first model is complement and {gamma}-chain-null/RAG2– (c–/{gamma}–/RAG2–) [24]. Initially, the lower limbs (n = 9) were subjected to 18-Gray irradiation to inhibit endogenous muscle satellite cell proliferation [25]. Three days later, the tibialis anterior muscles of both limbs were subjected to cryodamage by a 10-second application of a cryoprobe. This was repeated twice after thawing of the frozen muscle, before transplanting 5 x 105 hfMSCs in 5 µl of phosphate-buffered saline (PBS) [26]. The right tibialis anterior was transplanted with hfMSCs prestimulated in galectin-1 for 3 days, whereas hfMSCs exposed to nontransfected COS-1 medium was transplanted on the left. Muscles were harvested after 28 days and snap-frozen in cooled isopentane, and 6-µm transverse cryosections were collected on polylysine coated slides. Immunostaining for lamins A/C, spectrin, and desmin was performed as described below.

scid/mdx Mice.   The scid/mdx [27], which was derived by crossing dystrophic mdx mice [28] with scid mice [29], was used for transplantation. Two-month-old scid/mdx mice were anaesthesized with ketamine hydrochloride (80 mg/kg) and xylazine (10 mg/kg). hfMSCs with or without 3 days of pretreatment with galectin-1 were transplanted into the tibialis anterior muscle as described above (n = 3).

Immunohistochemistry and Cytochemistry
Primary antibodies used for immunochemical analysis were mouse monoclonal anti-desmin (DAKO, Glostrup, Denmark, http://www.dako.com), anti-sarcomeric myosin (MF20), anti-Pax7 (Developmental Hybridoma Bank of Iowa, Iowa City, IA [30]), anti-Myogenin, anti-MyoD1 (DAKO), anti-human lamins A/C, anti-human spectrin (Novocastra Ltd., Newcastle upon Tyne, U.K., http://www.novocastra.co.uk), and rabbit anti-desmin (Sigma-Aldrich). Immunophenotyping of cells was performed with mouse monoclonal anti-CD14, CD29, CD31, CD34, CD44, CD45, CD49b/d/e (BD Pharmingen, San Diego, http://www.bdbiosciences.com/pharmingen), CD105, SH3, SH4, CD106, vimentin, laminin, fibronectin, Von Willebrand factor (vWF), human leukocyte antigen (HLA)-DR, and HLA-I (DAKO, except that CD105, SH3, and SH4 were from Osiris Therapeutics, Baltimore, http://www.osiristx.com).

Cells were fixed in methanol:acetone 1:1 (vol/vol) for 5 minutes at room temperature and blocked with nonserum protein block (X0909; DAKO). For Pax7, MyoD, and Myogenin, cells were additionally incubated with 0.2% Triton X-100 to permeabilize the nuclear envelope. Thereafter, incubation with the appropriate primary antibody (desmin, 1:200; MF20, 1:10; Pax7, 1:50; MyoD, 1:100; Myogenin, 1:100) for 1 hour at room temperature, with subsequent incubations with a biotinylated secondary antibody (Vector Laboratories, Burlingame, CA, http://www.vectorlabs.com) followed by streptavidin-conjugated fluorochromes Alexafluor 488 and 594 (Invitrogen, Carlsbad, CA, http://www.invitrogen.com). Slides were then treated with 4,6-diamidino-2-phenylindole (H-1200; Vector Laboratories) and analyzed by epifluorescence microscopy (Axioscope I; Carl Zeiss, Jena, Germany, http://www.zeiss.com). Images were captured using a cooled charge-coupled device camera and reviewed in Quipps m-FISH software (Vysis, Abott Laboratories, Berkshire, U.K., http://www.vysis.com/).

Muscle sections were air-dried and blocked with 5% goat serum, 5% fetal calf serum, and papain-digested whole fragments of unlabeled secondary anti-mouse immunoglobulin [31] for 1 hour at room temperature, before incubation with monoclonal anti-lamins A/C (1:400), anti-spectrin (1:20), and rabbit anti-desmin (1:50) antibodies at 4°C overnight. A secondary fluorescein-conjugated goat anti-rabbit IgG (Vector Laboratories) was then used to label the desmin, and a biotinylated goat anti-mouse and streptavidin-conjugated Alexafluor 488 or 594 fluorochrome was used to label lamins A/C and spectrin.

Western Blot
Unstimulated hfMSCs, galectin-1-stimulated hfMSCs, and C2C12 cells were washed with ice-cold PBS, collected (by scraping), and centrifuged. Cell pellets were then resuspended in 1% SDS (Sigma-Aldrich) and heated for 5 minutes at 90°C. Resulting whole cell lysates were centrifuged at 13,000g at 4°C for 5 minutes, and the supernatant was collected. Protein concentrations were calculated by the bicinchoninic acid method (Pierce, Rockford, IL, http://www.piercenet.com). Fifty µg of protein was denatured by boiling for 5 minutes, resolved on 10% SDS-polyacrylamide gel, and transferred to Hybond P membrane (Amersham, GE Healthcare, Buckinghamshire, U.K., http://www.amersham.com/) in a semidry chamber with a three-buffer system as previously described [32]. The membranes were blocked overnight at 4°C in blotto (5% nonfat dried milk, vol/vol, in Tris-buffered saline plus 0.1% Tween). The membranes were incubated in mouse 1:1,000 anti-desmin (DAKO) antibody in blotto for 1 hour, followed by incubation in goat anti-mouse horseradish peroxidase-conjugated antibody (DAKO) in blotto for 1 hour. After washing, chemiluminescence ECL Plus system (Amersham Pharmacia Biotech) was used for signal detection, and the membrane was subsequently exposed onto autoradiography films.

Semiquantitative Reverse Transcriptase Polymerase Chain Reaction
Total RNA was isolated from hfMSCs exposed to galectin-1 for various durations (0–12 days) using RNeasy kit (Qiagen, Hilden, Germany, http://www1.qiagen.com) according to the manufacturer’s instructions and quantified spectrophotometrically. Complementary DNA were obtained by reverse transcriptase of 1 mg of total RNA using oligo(dT)15 primer and the reverse transcription system kit (A3500; Promega, Madison, WI, http://www.promega.com). Polymerase chain reactions (PCRs) were carried out using specific primers derived from published cDNA sequences (Invitrogen) (Table 1). Negative controls were either reverse transcriptase (RT) without enzyme or PCR with Mili-Q (Millipore, Brussels, Belgium) ultrapure water instead of cDNA. Amplification of the control RNA without reverse transcription did not generate any products in PCRs (data not shown). Following PCR, the products were electrophoresed in ethidium-bromide agarose gels photographed under UV light. 18SRNA were used as a loading control, and fetal muscle (17 weeks of gestation) was used as a positive control.


View this table:
[in this window]
[in a new window]
  		Table 1. PCR primers

 
Statistics
Parametric variables were expressed as mean and standard deviations and compared by Student’s t test or one-way analysis of variance as appropriate. Nonparametric data were compared by the Wilcoxon signed rank test. A p value of <.05 was considered significant.


   RESULTS
Top
 Abstract
 Introduction
 Materials and Methods
 Results
Discussion
 Disclosures
 Acknowledgments
 References
 
When 106 mononuclear cells from fetal blood or BM were plated, adherent spindle-shaped cells were seen, which rapidly formed colonies over 2–3 days. After removal of nonadherent cells, these colonies grew rapidly to subconfluence, whereby they were trypsinized and replated at low density. Characterization via immunocytochemical staining in some of the samples at passage 2 revealed a consistent immunophenotype as previously reported [9], which was negative for hemopoietic and endothelial markers CD34, CD45, CD14, CD31, and vWF and positive for mesenchymal markers CD105 (SH2), SH3, SH4, and vimentin and cell adhesion molecules CD29; {alpha}2, {alpha}4, and {alpha}5 integrin (CD49b, CD49d, and CD49e); CD44; CD106 (VCAM-1); laminin; and fibronectin. They did not express HLA-II and have low levels of HLA-I. In permissive media, they differentiated readily into osteoblasts and adipocytes. Comparable populations of adult BM MSCs had an immunophenotype and a differentiation capacity similar to those of hfMSCs.

In Vitro Muscle Differentiation
To induce in vitro myogenesis, we exposed hfMSCs to a variety of stimuli.

5-Azacytidine.   We exposed hfMSCs (n = 10) to 1–24 µM 5-azacytidine (concentrations similar to those published on myogenic induction of rodent or rabbit MSCs [33, 34]) over varying time points (6–48 hours) and multiple exposures in various culture media (serum-free, low-serum, and 10% fetal calf serum) and substrata (glass, plastic, Matrigel, and fibronectin). We found no evidence of any myogenic differentiation but noted massive cell death. Similarly, adult BM MSCs responded in a similar fashion with death of most of the cells without any expression of myogenic markers in surviving cells.

Horse Serum, Dexamethasone, and Hydrocortisone.   Next, we exposed hfMSCs (n = 3) to a mixture of horse serum, dexamethasone, and hydrocortisone over 12 days but did not find any myotube formation or the expression of any myogenic markers.

Conditioned Medium.   Following this, we investigated whether conditioned media [35–37] from myoblast cultures could induce myogenic differentiation. After 7 days of culture in C2C12 myoblast-conditioned medium (1:2–4 conditioned/serum-free medium), a small number of desmin-staining cells (1–2 positive cells or myotubes per low-powered field) were present. After 14 days, long, multinucleated, desmin-positive fibers were evident, which stained positively for the muscle markers desmin and sarcomeric myosin. However, the conversion efficiency of hfMSCs approached only 1%–2% (Fig. 1A–1D, 1G). Culture of adult BM MSCs under identical conditions failed to result in muscle differentiation. Immunostaining of control C2C12 myoblasts revealed desmin expression in all cells, but the more mature muscle-specific protein, myosin, was only expressed upon myotube formation (Fig. 1E, 1F).


Figure 1
View larger version (90K):
[in this window]
[in a new window]
  		Figure 1. Induction of muscle differentiation with myoblast-conditioned medium. (A–D): Desmin immunostaining (green) of human fetal mesenchymal stem cells (hfMSCs) from 0 through 14 days in the presence of myoblast-conditioned medium with the appearance of long, multinucleated, desmin-positive fibers over 14 days (A–C) (original magnification, x16). Sarcomeric myosin expression (green, MF20) could be detected in a few fibers after 14 days of culture in myoblast-conditioned medium (D). Nuclei stained with 4,6-diamidino-2-phenylindole (blue) (original magnification, x16). (E, F): Control C2C12 murine myoblasts all express desmin (E) (green), whereas only terminally differentiated C2C12 in myotubes express sarcomeric myosin, a protein expressed only following terminal differentiation (F). (G): Desmin immunostaining (blue) using alkaline phosphatase with blue substrate demonstrating multinucleated desmin-positive myotube after 14 days of culture of hfMSCs with myoblast-conditioned medium (G).

 

Galectin-1.   Next, we examined the ability of galectin-1 to induce myogenic differentiation in hfMSCs. After exposure of fetal blood or fetal BM-derived hfMSCs to galectin-1-enriched serum-free medium (200 ng/ml galectin-1), the appearance of desmin-positive single cells at day 3, followed by the formation of desmin-positive multinucleated fibers over the next 9 days in culture was observed. The percentage of desmin-positive cells increased over time, reaching a peak after 12 days of 66.1% ± 5.7% (mean ± SD) of total cells in culture (Fig. 2A–2E, 2G), most of which were incorporated into myotubes (3–23 nuclei per fiber). The latest time point examined was 12 days, as culture beyond this time resulted in the lifting of the myotubes from the plate. Western blots confirmed the accumulation of desmin only in galectin-1-stimulated cells (Fig. 2F). In a similar manner, the expression of sarcomeric myosin (MF20) increased over time to reach a peak of 63.0% ± 7.5% (mean ± SD) (Fig. 3A–3F).


Figure 2
View larger version (90K):
[in this window]
[in a new window]
  		Figure 2. Desmin expression with galectin-1 stimulation. (A–F): Incubation of hfMSCs in the presence of galectin-1-enriched medium resulted in the appearance of desmin (green) positive cells by day 3 (A), increasing to a maximum on day 12 (B–E). Desmin-positive cells started to fuse into multinucleated fibers by day 6, with some fibers displaying more than 20 nuclei (original magnification, x16). Western blot for desmin: Lane 1, positive control from C2C12 cells (53 kDa); lane 2, unstimulated hfMSCs; lane 3, COS-1 medium-stimulated hfMSCs; lane 4, unstimulated hfMSCs; lane 5, day 12 galectin-1-stimulated hfMSCs. (G–I): The percentage of cells positive for desmin (mean ± SE) over time in culture with galectin-1 increased over time to 65% after 12 days of exposure (G). Comparison of percentage of 6 Gal versus 6 Gal, 6 SF versus 12 Gal (H). Galectin-1 concentration and the percentage of desmin-positive cells (mean ± SE) in hfMSCs after 12 days exposure (I). Abbreviations: 6 Gal, cells positive for desmin after 6 days of galectin-1 exposure; 6 Gal, 6 SF, 6 days of galectin-1 exposure followed by removal of galectin-1 for another 6 days; 12 Gal, continuous galetin-1 exposure over 12 days; hfMSC, human fetal mesenchymal stem cell; Pos Ctrl, positive control.

 


Figure 3
View larger version (80K):
[in this window]
[in a new window]
  		Figure 3. Myosin expression with galectin-1 stimulation. (A–E): Immunostaining of human fetal mesenchymal stem cells (hfMSCs) with MF20 demonstrated an increase in the proportion of hfMSCs expressing sarcomeric myosin with galectin-1 stimulation. The increase in sarcomeric myosin expression mirrors that of desmin expression with galectin-1 stimulation (F).

 
When hfMSCs were exposed to various concentrations of galectin-1, the highest proportion of desmin-positive cultures (65.9% ± 8.0%) was achieved with 200 ng/ml of galectin-1. Higher concentrations of galectin-1 (400 and 1,000 ng/ml) resulted in significant cell death with fewer desmin-positive cells (10.0% ± 3.9% and 4.5% ± 1.7%, respectively), whereas lower dilutions (100 ng/ml), fewer desmin-positive cells were seen (44.9% ± 18.2%; Fig. 2H) (p < .0001).

In a separate experiment, continuous exposure of hfMSCs to galectin-1 over 12 days resulted in the development of multinucleated desmin-positive fibers in 62.3% ± 7.8% of cells, whereas a shorter exposure of 6 days followed by removal of galectin-1, and then 6 days of culture in serum-free medium resulted in 39.1% ± 2.3% of cells positively staining for desmin (p < .001). Exposure of hfMSCs to 6 days of galectin-1 followed by immediate staining for desmin resulted in only 18.5% ± 5.2% desmin-positive cells (p < .001) (Fig. 2I). Although hfMSCs grown in serum-free media failed to proliferate in culture, the addition of galectin-1 stimulated a mitogenic response, with a doubling time of 120 ± 10 hours (mean ± SD) as compared with 30 ± 4 hours when grown in the presence of serum. This compares with a doubling time of 115 ± 7 hours for adult BM MSCs grown in D10.

Prior to myogenic induction, both hfMSCs and adult BM MSCs were negative for markers of the muscle lineage, including desmin, myosin, Pax7, MyoD, and Myogenin on immunocytochemistry. In contrast, exposure of adult BM-derived MSCs to galectin-1 for up to 12 days did not result in the appearance of any desmin/myosin-positive cells or multinucleated myotubes.

Expression of Myogenic Regulatory Factors.   A time course examination of nuclear Pax7 expression using immunocytochemical staining revealed a gradual increase in the proportion of Pax7-positive hfMSCs, with 0%, 6.7%, 11.1%, 14.7%, and 24.2% of cells staining positive at 0, 3, 6, 9, and 12 days, respectively (Fig. 4F). In contrast, control C2C12 myoblast cells undergoing terminal differentiation in low serum culture were negative for Pax7. MyoD expression increased in a similar fashion, with 0%, 7.6%, 8.4%, 20.0%, and 20.4% of cells staining positive at 0, 3, 6, 9, and 12 days, respectively (Fig. 4A–4F). The expression of Myogenin also increased sequentially, with 0%, 1.9%, 5.8%, 5.5%, and 9.5% of cells being positive on day 0, 3, 6, 9, and 12 respectively (Fig. 4F). Analysis of the MRFs at the mRNA level revealed the transient upregulation of Myf5 from day 3 through day 6, Pax7 during days 3–9, and MyoD and myogenin from day 3 to day 12. Expression of both desmin and myosin heavy chain transcripts, though negative on immunocytochemical staining and Western blotting, was positive in naïve undifferentiated hfMSCs and upregulated through the 12 days of galectin-1 stimulation. Dystrophin mRNA was upregulated by day 9 of exposure to galectin-1 (Fig. 4G).


Figure 4
View larger version (33K):
[in this window]
[in a new window]
  		Figure 4. Expression of muscle regulatory factors with galectin-1 stimulation. (A–E): Time course expression of MyoD (green) in the nucleus of human fetal mesenchymal stem cells (hfMSCs) during galectin-1 stimulation over time. There was a similar increase in the proportion of cells expressing Pax7 and Myogenin during galectin-1 stimulatin (F). Reverse transcriptase-polymerase chain reaction of various myogenic markers (Myf5, Pax7, MyoD, Myogenin, desmin, myosin HC, and dystrophin) in hfMSCs over time (days 0, 3, 6, 9, and 12) in the presence of galectin-1. Millipore ultrapure water was used as a negative control, whereas human fetal muscle was used as the positive control (G). Abbreviations: bp, base pairs; D, day(s); HC, heavy chain.

 
Differentiation of Engrafted Cells After In Vivo Transplantation into Injured and Dystrophic Muscle
To investigate whether hfMSCs could contribute to muscle regeneration in vivo, we used an in vivo injury model in the c–/{gamma}–/RAG2– mouse. Initial pilot experiments revealed that intramuscular transplantation of naïve hfMSCs resulted in the formation of small numbers of human muscle fibers after 28 days (1–10 per muscle section). We then investigated whether prestimulation of hfMSCs with galectin-1 for 3 days would improve differentiation. After i.m. transplantation with galectin-1-prestimulated hfMSCs, a median of 44 (range, 20–93) human spectrin-positive muscle fibers per muscle section was found (Fig. 5A), whereas only 11 (range 3–26) human spectrin-positive fibers were seen in the contralateral muscle transplanted with nonstimulated hfMSCs after 28 days (Fig. 5B) (Wilcoxon signed ranked test, p = .008). This is against a background of 900–1,450 muscle fibers per cross section of the tibialis anterior muscle (i.e., ≤4%). Some human spectrin-positive muscle fibers displayed centrally located nuclei, indicating regenerated fibers (Fig. 5A). Double labeling with antibodies against human lamins A/C (components of the human nuclear membrane) and human spectrin indicated the human origin of these centrally-located nuclei (Fig. 5C). These spectrin-positive fibers could be traced along the tibialis anterior muscle by immunolabeling serial sections. H&E staining revealed some areas infiltrated with amorphous fibrous tissue that encased human cells revealed by lamin A/C staining (Fig. 5D). These cells of human origin did not express desmin (Fig. 5E), showing that they were nonmyogenic. Nontransplanted control muscle contained no cells staining for human lamins A/C and spectrin.


Figure 5
View larger version (66K):
[in this window]
[in a new window]
  		Figure 5. Transplantation of human fetal mesenchymal stem cells (hfMSCs) into regenerating murine muscle. (A–C): Transverse section of tibialis anterior muscle transplanted with either naïve hfMSCs (A) or galectin-1-pretreated hfMSCs (B) showing numerous small human muscle fibers. Centrally located nuclei were found in most spectrin-positive fibers, indicating regenerated muscle fibers. (A, inset) (original magnification, x16). By double staining the sections with human-specific lamins A/C, one could identify human nuclei (red nucleus) within human muscle fibers (human sarcolemmal spectrin in red) (C) (original magnification, x100). Adjacent section of transplanted muscle with H&E staining displaying numerous nuclei (yellow arrows) within amorphous connective tissue in between the muscle fiber (D) (original magnification, x16). Triple staining of transplanted murine muscle showing numerous human nuclei (lamins A/C, nuclear pink) situated in between murine muscle fibers (desmin, green) with a single human muscle fiber (spectrin, red ring [arrow]). The human cells seen here were mainly found in between the muscle fibers, and most did not express the muscle marker desmin (E) (original magnification, x16). Abbreviation: DAPI, 4,6-diamidino-2-phenylindole.

 
To further investigate the participation of hfMSCs in regenerating dystrophic fibers, we injected hfMSCs into the immunodeficient scid/mdx dystrophic mouse [27]. After i.m. delivery, only galectin-1-prestimulated hfMSCs formed clusters of spectrin-positive fibers (a mean of 32.8 ± 20.2 per section) against a background of approximately 1,000 fibers per muscle fiber (Fig. 6A–6D). In contrast, none of the non-galectin-1-stimulated hfMSCs formed any human spectrin-positive muscle fibers or expressed any muscle marker such as desmin.


Figure 6
View larger version (56K):
[in this window]
[in a new window]
  		Figure 6. Transplantation of hfMSCs into scid/mdx mice. (A–D): Intramuscular transplantation of naïve hfMSCs into scid/mdx tibialis anterior muscle labeled with human lamins A/C (green), showing numerous human cells within the transplanted muscle (A) without any evidence of muscle differentiation when double-labeled with human spectrin (B). In contrast, galectin-1-prestimulated hfMSCs engrafted (C) and formed numerous spectrin-positive fibers (D) after 28 days (original magnification, x10). Abbreviation: hfMSC, human fetal mesenchymal stem cell.

 

   DISCUSSION
Top
 Abstract
 Introduction
 Materials and Methods
 Results
 Discussion
Disclosures
 Acknowledgments
 References
 
The recent discovery of a novel population of MSCs in the human fetus that displays multilineage differentiation in vitro [9] and in vivo [38] led us to hypothesize that hfMSCs can differentiate into muscle and participate in muscle regeneration. Although hfMSCs did not differentiate to skeletal muscle in vitro in response to 5-azacytidine or a combination of horse serum, dexamethasone, and hydrocortisone, we found that a soluble factor within myoblast-conditioned medium resulted in muscle differentiation in a small proportion of cells. As recent work in our laboratory suggested that the soluble factor responsible for myogenic conversion of dermal fibroblast was galectin-1 [23], we tested the ability of galectin-1 to induce myogenic differentiation in hfMSCs. We report that this resulted in significant recruitment of hfMSCs into the myogenic lineage and formation of mature myotubes. This occurred via activation of the myogenic regulatory factors in a manner reminiscent of that which occurs during embryonic myogenesis [39]. Although hfMSCs contributed to muscle formation in a murine model of muscle regeneration, prestimulation of hfMSCs with galectin-1 for a short period of time resulted in the formation of substantially more muscle than with naïve hfMSCs.

The use of 5-azacytidine for myogenic differentiation of MSCs was described in immortalized rodent and rabbit MSCs [33, 34] via stochastic hypomethylation of random DNA residues [40], which in turn results in the activation of myogenic regulatory factors. Although there are no reports of successful myogenic conversion of adult BM-derived MSCs with 5-azacytidine in humans, this approach produced low levels of myogenic conversion of synovial membrane-derived human MSCs [41]. Notwithstanding this, high-efficiency conversion has been achieved with a subpopulation of human BM-derived stem cells called multipotent adult progenitor cells, although there was no confirmation that these generated myotubes [42]. Our finding of massive cell death in both hfMSCs and adult MSCs with 5-azacytidine is consistent with experience in human adult BM-derived MSCs, where there is a paucity of published literature to demonstrate myogenic differentiation. The use of a combination of horse serum, hydrocortisone, and dexamethasone was first described by Zuk et al. in adiposal-derived MSCs [21, 22] and later used by Gang et al. in umbilical cord blood-derived MSCs [43] for induction of myogenic differentiation. This, however, did not result in any myogenic differentiation in hfMSCs. Although the use of proprietary skeletal muscle differentiation medium (Promocell) has been reported to induce muscle differentiation in adipose-derived MSCs [44], we have not tested this in hfMSCs. Exposure to myoblast-conditioned media resulted in a small proportion of hfMSCs, but not adult BM MSCs, acquiring muscle-specific markers and, unlike dermal fibroblasts, fusion to form myotubes [35, 36].

Galectin-1, a 14–15-kDa lectin, belongs to a family of animal ß-galactoside-binding proteins that are highly conserved during evolution [45–47]. It is secreted by myoblasts in culture [48] and has a diverse variety of biological activities [49]. Under different circumstances, it may act as a mitogen, an inhibitor of cell proliferation, a promoter of apoptosis [50], and, as we have previously shown, it is implicated in skeletal muscle determination [23, 51]. Interestingly, gene profiling showed that galectin-1 is one of the most commonly expressed genes and proteins in adult bone marrow-derived MSCs [52, 53]. As our previous work has implicated galectin-1 to be the soluble factor responsible for myogenic conversion of dermal fibroblasts [23, 54], we extended this work by exposing hfMSCs to galectin-1 to find efficient myogenic conversion with formation of mature myotubes in vitro. This contrasted with dermal fibroblasts, which did not form mature myotubes in vitro. Continuous galectin-1 exposure over 12 days resulted in significantly higher proportion of hfMSCs entering myogenic differentiation than cells exposed for 6 days followed by the removal of galectin-1 and subsequent culture for 6 days under serum-free conditions. This suggested that either cells entering myogenic differentiation have a proliferative advantage over others, or that continued galectin-1 stimulation resulted in a higher proportion of cells recruited into the myogenic lineage. Interestingly, exposure of hfMSCs to 6 days of galectin-1 followed by immediate staining for desmin resulted in a much lower proportion of desmin-positive cells, suggesting that although the presence of galectin-1 is important for continued recruitment of noncommitted hfMSCs into the myogenic lineage, hfMSCs that have already initiated myogenic differentiation can still divide and proceed to terminal differentiation without continued galectin-1 stimulation. Galectin-1 also has a mitogenic effect on hfMSCs.

The level of in vitro myogenic conversion and myotube development we report here when hfMSCs were grown in galectin-1-enriched medium is considerably greater than previously reported in human MSC populations [8, 21, 41, 55] or even murine myoblast cultures [23]. de Bari et al. found only rare myogenic differentiation and little myotube formation with their human synovial membrane-derived MSCs [41], whereas Reyes et al., in reporting that up to 80% of human multipotent adult progenitor cells acquire muscle markers on exposure to 5-azacytidine, still did not find significant myotube formation [42]. Although Gang et al. recently demonstrated muscle differentiation by expression of myosin heavy chain in up to 56% of umbilical cord blood-derived MSCs after culture with horse serum, dexamethasone, and hydrocortisone, there was no morphological evidence of myotube formation [43]. Barberi et al. demonstrated that 10% of mesenchymal progenitor cells derived from human embryonic stem cells could fuse with C2C12 cells in coculture [56]. Recently, Dezawa et al. described a multistage myogenic induction program resulting in up to 40% of adult BM MSCs fusing to form myotubes, with clonal populations achieving an 89% fusion index [57]. However, this was accomplished via the transfection of a Notch 1 intracellular domain gene with selection via neomycin resistance within the plasmid, which may affect subsequent cell function/metabolism both in vitro [58, 59] and in vivo [60].

Galectin-1-induced myogenic differentiation is accompanied by the sequential expression of early, intermediate, and late MRFs (Myf5 and Pax7, MyoD, and Myogenin, respectively) differentiating in a stepwise manner into cells bearing a satellite cell immunophenotype (Pax7+) and finally into multinucleated mature muscle fibers in a manner reminiscent of that which occurs during embryonic myogenesis and skeletal muscle regeneration. This is in keeping with the in vivo finding of LaBarge et al. that bone marrow-derived cells undergo recruitment to muscle satellite cells and finally mature myofibers in a stepwise manner [61]. The finding that both desmin and myosin heavy chain was amplified by RT-PCR but the protein was not detected by immunocytochemical staining (desmin and myosin) or Western blot (desmin) in the naïve unstimulated hfMSCs shows the importance of looking for protein as well as gene expression, as small amounts of message may not have given rise to functional amounts of protein. This mirrors findings by Seshi et al. in adult bone marrow-derived MSCs, where both heterogeneous as well as clonal MSC populations were found to express multiple lineage genes, including those of the myogenic lineage such as myosin and dystrophin [62, 63].

To elucidate the role of hfMSCs in muscle repair, we used a well-established murine muscle injury model in which both soluble factors and cell-cell contact within regenerating muscle would influence myogenic specification of transplanted cells. Transplantation of galectin-1-prestimulated hfMSCs rather than naïve hfMSCs resulted in a fourfold increase in muscle fiber formation, suggesting that although local environmental cues of a regenerating muscle environment stimulate myogenesis in hfMSCs, the use of galectin-1 pre-stimulation potentiates the contribution of hfMSCs to skeletal muscle regeneration. The majority of transplanted cells within the muscle, however, did not undergo muscle differentiation and remained as nonmyogenic, desmin-negative cells. hfMSCs behaved in a similar fashion when transplanted into dystrophic scid/mdx mice muscle, with only galectin-1-prestimulated cells contributing to muscle regeneration.

Although both Carmargo et al. [64] and Corbel et al. [65] recently showed muscle formation in mouse models from the hemopoietic compartment of the bone marrow in mice, neither group completely ruled out MSC participation. There have been few reports of myogenic differentiation of human MSCs in vitro apart from MSCs derived from non-BM sources such as adipose tissue [21], synovial membrane [41], or umbilical cord blood [43]. We have demonstrated that a well-characterized population of human MSCs from fetal blood and BM undergoes myogenic differentiation with the formation of mature myotubes when stimulated with a soluble factor found in myoblast-conditioned medium. We speculated that the compound responsible is galectin-1 and confirmed this by showing far more impressive myogenic conversion of hfMSCs in vitro following galectin-1 stimulation. Our speculation is strengthened by the fact that prestimulation of hfMSCs with galectin-1 results in a fourfold increase in their contribution to muscle regeneration in injured murine muscle, confirming that galectin-1 is a crucial factor in increasing the myogenic conversion of hfMSCs to skeletal muscle in vivo as well as in vitro.

In summary, we have demonstrated efficient in vitro muscle differentiation with myotube formation of hfMSCs in response to galectin-1 in vitro and an increase in contribution to muscle regeneration in both an injury and dystrophic murine model after galectin-1 prestimulation. Although the mechanism by which galectin-1 switches on the myogenic regulatory factors and hence induces myogenic differentiation remains unknown, we suggest that hfMSCs may be a promising source of cells for the autologous or allogeneic treatment of genetic/degenerative muscle diseases and serve as an important model of myogenic cell specification/differentiation. Further investigations are now under way to increase the level of hfMSCs contribution to muscle regeneration and to elucidate the mechanism by which galectin-1 myogenic differentiation occurs in hfMSCs.


   DISCLOSURES
Top
 Abstract
 Introduction
 Materials and Methods
 Results
 Discussion
 Disclosures
Acknowledgments
 References
 
K.O. received salary support from Action Medical Research, U.K. N.K. was funded by a research training fellowship from the Wellcome Trust, U.K. J.E.M. received funding from the Muscular Dystrophy Campaign and the MRC, U.K. D.W. received funding for the galectin-1 work from the Muscular Dystrophy Campaign.


   ACKNOWLEDGMENTS
Top
 Abstract
 Introduction
 Materials and Methods
 Results
 Discussion
 Disclosures
 Acknowledgments
References
 
We thank Prof. Terence Partridge for his helpful suggestions and advice, Dr. Briana Cloke for help with western blotting, and Karimah Brimah and Janine Ehrhardt for help with immunohistochemistry. This study was funded by the Institute of Obstetrics and Gynaecology Trust.


   REFERENCES
Top
 Abstract
 Introduction
 Materials and Methods
 Results
 Discussion
 Disclosures
 Acknowledgments
 References
 

  1. Seale P, Rudnicki MA. A new look at the origin, function, and "stem-cell" status of muscle satellite cells. Dev Biol 2000;218:115–124.[CrossRef][Medline]

  2. Grounds MD. Towards understanding skeletal muscle regeneration. Pathol Res Pract 1991;187:1–22.[Medline]

  3. Gussoni E, Soneoka Y, Strickland CD et al. Dystrophin expression in the mdx mouse restored by stem cell transplantation. Nature 1999;401:390–394.[CrossRef][Medline]

  4. Ferrari G, Cusella-De Angelis G, Coletta M et al. Muscle regeneration by bone marrow-derived myogenic progenitors. Science 1998;279:1528–1530.[Abstract/Free Full Text]

  5. Bittner RE, Schofer C, Weipoltshammer K et al. Recruitment of bone-marrow-derived cells by skeletal and cardiac muscle in adult dystrophic mdx mice. Anat Embryol (Berl) 1999;199:391–396.[CrossRef][Medline]

  6. Shi D, Reinecke H, Murry CE et al. Myogenic fusion of human bone marrow stromal cells, but not hematopoietic cells. Blood 2004;104:290–294.[Abstract/Free Full Text]

  7. de Bari C, Dell’Accio F, Vandenabeele F et al. Skeletal muscle repair by adult human mesenchymal stem cells from synovial membrane. J Cell Biol 2003;160:909–918.[Abstract/Free Full Text]

  8. Muguruma Y, Reyes M, Nakamura Y et al. In vivo and in vitro differentiation of myocytes from human bone marrow-derived multipotent progenitor cells. Exp Hematol 2003;31:1323–1330.[CrossRef][Medline]

  9. Campagnoli C, Roberts IA, Kumar S et al. Identification of mesenchymal stem/progenitor cells in human first-trimester fetal blood, liver, and bone marrow. Blood 2001;98:2396–2402.[Abstract/Free Full Text]

  10. Gotherstrom C, Ringden O, Westgren M et al. Immunomodulatory effects of human foetal liver-derived mesenchymal stem cells. Bone Marrow Transplant 2003;32:265–272.[CrossRef][Medline]

  11. Chan J, O’Donoghue K, de la Fuente J et al. Human fetal mesenchymal stem cells as vehicles for gene delivery. STEM CELLS 2005;23:93–102.[Abstract/Free Full Text]

  12. Kennea NL, Fisk NM, Edwards AD et al. Neural cell differentiation of fetal mesenchymal stem cells. Early Hum Dev 2003;73:121a–122a.

  13. Orlandi F, Damiani G, Jakil C et al. The risks of early cordocentesis (12–21 weeks): Analysis of 500 procedures. Prenat Diagn 1990;10:425–428.[Medline]

  14. Surbek DV, Tercanli S, Holzgreve W. Transabdominal first trimester embryofetoscopy as a potential approach to early in utero stem cell transplantation and gene therapy. Ultrasound Obstet Gynecol 2000;15:302–307.[CrossRef][Medline]

  15. Surbek DV, Young A, Danzer E et al. Ultrasound-guided stem cell sampling from the early ovine fetus for prenatal ex vivo gene therapy. Am J Obstet Gynecol 2002;187:960–963.[CrossRef][Medline]

  16. Zanjani ED, Anderson WF. Prospects for in utero human gene therapy. Science 1999;285:2084–2088.[Abstract/Free Full Text]

  17. Le Blanc K, Gotherstrom C, Ringden O et al. Fetal mesenchymal stem cell engraftment in bone following in utero transplantation in a patient with severe osteogenesis imperfecta. Transplantation 2005;79:1607–1614.[CrossRef][Medline]

  18. Polkinghorne J. Review of the Guidance on the Research Use of Fetus and Fetal Material. CM 762. London: Her Majesty’s Stationary Office, 1989;.

  19. O’Donoghue K, Chan J, De La Fuente J et al. Microchimerism in female bone marrow and bone decades after fetal mesenchymal stem-cell trafficking in pregnancy. Lancet 2004;364:179–182.[CrossRef][Medline]

  20. Yaffe D, Saxel O. Serial passaging and differentiation of myogenic cells isolated from dystrophic mouse muscle. Nature 1977;270:725–727.[CrossRef][Medline]

  21. Zuk PA, Zhu M, Mizuno H et al. Multilineage cells from human adipose tissue: Implications for cell-based therapies. Tissue Eng 2001;7:211–228.[CrossRef][Medline]

  22. Zuk PA, Zhu M, Ashjian P et al. Human adipose tissue is a source of multipotent stem cells. Mol Biol Cell 2002;13:4279–4295.[Abstract/Free Full Text]

  23. Goldring K, Jones GE, Thiagarajah R et al. The effect of galectin-1 on the differentiation of fibroblasts and myoblasts in vitro. J Cell Sci 2002;115:355–366.[Abstract/Free Full Text]

  24. Morgan JE, Gross JG, Pagel CN et al. Myogenic cell proliferation and generation of a reversible tumorigenic phenotype are triggered by preirradiation of the recipient site. J Cell Biol 2002;157:693–702.[Abstract/Free Full Text]

  25. Wakeford S, Watt DJ, Partridge TA. X-irradiation improves mdx mouse muscle as a model of myofiber loss in DMD. Muscle Nerve 1991;14:42–50.[CrossRef][Medline]

  26. Irintchev A, Langer M, Zweyer M et al. Functional improvement of damaged adult mouse muscle by implantation of primary myoblasts. J Physiol 1997;500:775–785.[Medline]

  27. Torrente Y, Belicchi M, Sampaolesi M et al. Human circulating AC133(+) stem cells restore dystrophin expression and ameliorate function in dystrophic skeletal muscle. J Clin Invest 2004;114:182–195.[CrossRef][Medline]

  28. Sicinski P, Geng Y, Ryder-Cook AS et al. The molecular basis of muscular dystrophy in the mdx mouse: A point mutation. Science 1989;244:1578–1580.[Abstract/Free Full Text]

  29. Bosma GC, Custer RP, Bosma MJ. A severe combined immunodeficiency mutation in the mouse. Nature 1983;301:527–530.[CrossRef][Medline]

  30. Bader D, Masaki T, Fischman DA. Immunochemical analysis of myosin heavy chain during avian myogenesis in vivo and in vitro. J Cell Biol 1982;95:763–770.[Abstract/Free Full Text]

  31. Lu QL, Partridge TA. A new blocking method for application of murine monoclonal antibody to mouse tissue sections. J Histochem Cytochem 1998;46:977–984.[Abstract/Free Full Text]

  32. Pohnke Y, Kempf R, Gellersen B. CCAAT/enhancer-binding proteins are mediators in the protein kinase A-dependent activation of the decidual prolactin promoter. J Biol Chem 1999;274:24808–24818.[Abstract/Free Full Text]

  33. Wakitani S, Saito T, Caplan AI. Myogenic cells derived from rat bone marrow mesenchymal stem cells exposed to 5-azacytidine. Muscle Nerve 1995;18:1417–1426.[CrossRef][Medline]

  34. Rangappa S, Fen C, Lee EH et al. Transformation of adult mesenchymal stem cells isolated from the fatty tissue into cardiomyocytes. Ann Thorac Surg 2003;75:775–779.[Abstract/Free Full Text]

  35. Wise CJ, Watt DJ, Jones GE. Conversion of dermal fibroblasts to a myogenic lineage is induced by a soluble factor derived from myoblasts. J Cell Biochem 1996;61:363–374.[CrossRef][Medline]

  36. Salvatori G, Lattanzi L, Coletta M et al. Myogenic conversion of mammalian fibroblasts induced by differentiating muscle cells. J Cell Sci 1995;108Pt 8:2733–2739.[Abstract]

  37. Breton M, Li ZL, Paulin D et al. Myotube driven myogenic recruitment of cells during in vitro myogenesis. Dev Dyn 1995;202:126–136.[Medline]

  38. MacKenzie TC., Campagnoli C, Almeida-Porada G et al. Circulating human fetal stromal cells engraft and differentiate in multiple tissues following transplantation into pre-immune fetal lambs. Blood 2001;98:798a.

  39. Seale P, Sabourin LA, Girgis-Gabardo A et al. Pax7 is required for the specification of myogenic satellite cells. Cell 2000;102:777–786.[CrossRef][Medline]

  40. Santi DV, Norment A, Garrett CE. Covalent bond formation between a DNA-cytosine methyltransferase and DNA containing 5-azacytosine. Proc Natl Acad Sci U S A 1984;81:6993–6997.[Abstract/Free Full Text]

  41. de Bari C, Dell’Accio F, Tylzanowski P et al. Multipotent mesenchymal stem cells from adult human synovial membrane. Arthritis Rheum 2001;44:1928–1942.[CrossRef][Medline]

  42. Reyes M, Lund T, Lenvik T et al. Purification and ex vivo expansion of postnatal human marrow mesodermal progenitor cells. Blood 2001;98:2615–2625.[Abstract/Free Full Text]

  43. Gang EJ, Jeong JA, Hong SH et al. Skeletal myogenic differentiation of mesenchymal stem cells isolated from human umbilical cord blood. STEM CELLS 2004;22:617–624.[Abstract/Free Full Text]

  44. Rodriguez AM, Pisani D, Dechesne CA et al. Transplantation of a multipotent cell population from human adipose tissue induces dystrophin expression in the immunocompetent mdx mouse. J Exp Med 2005;201:1397–1405.[Abstract/Free Full Text]

  45. Barondes SH, Castronovo V, Cooper DN et al. Galectins: A family of animal beta-galactoside-binding lectins. Cell 1994;76:597–598.[CrossRef][Medline]

  46. Barondes SH, Cooper DN, Gitt MA et al. Galectins. Structure and function of a large family of animal lectins. J Biol Chem 1994;269:20807–20810.[Free Full Text]

  47. Hirabayashi J, Kasai K. The family of metazoan metal-independent beta-galactoside-binding lectins: Structure, function and molecular evolution. Glycobiology 1993;3:297–304.[Abstract/Free Full Text]

  48. Harrison FL, Wilson TJ. The 14 kDa beta-galactoside binding lectin in myoblast and myotube cultures: Localization by confocal microscopy. J Cell Sci 1992;101:635–646.[Abstract/Free Full Text]

  49. Smetana K Jr, Lukas J, Paleckova V et al. Effect of chemical structure of hydrogels on the adhesion and phenotypic characteristics of human monocytes such as expression of galectins and other carbohydrate-binding sites. Biomaterials 1997;18:1009–1014.[CrossRef][Medline]

  50. Scott K, Weinberg C. Galectin-1: a bifunctional regulator of cellular proliferation. Glycoconj J 2004;19:467–477.[CrossRef][Medline]

  51. Watt DJ, Jones GE, Goldring K. The involvement of galectin-1 in skeletal muscle determination, differentiation and regeneration. Glycoconj J 2004;19:615–619.[CrossRef][Medline]

  52. Silva WA Jr., Covas DT, Panepucci RA et al. The profile of gene expression of human marrow mesenchymal stem cells. STEM CELLS 2003;21:661–669.[Abstract/Free Full Text]

  53. Kadri T, Lataillade JJ, Doucet C et al. Proteomic study of Galectin-1 expression in human mesenchymal stem cells. Stem Cells Dev 2005;14:204–212.[CrossRef][Medline]

  54. Goldring K, Jones GE, Sewry CA et al. The muscle-specific marker desmin is expressed in a proportion of human dermal fibroblasts after their exposure to galectin-1. Neuromuscul Disord 2002;12:183–186.[CrossRef][Medline]

  55. Mizuno H, Zuk PA, Zhu M et al. Myogenic differentiation by human processed lipoaspirate cells. Plast Reconstr Surg 2002;109:199–209 discussion 210–211.

  56. Barberi T, Willis LM, Socci ND et al. Derivation of multipotent mesenchymal precursors from human embryonic stem cells. PLoS Med 2005;2:e161.[CrossRef][Medline]

  57. Dezawa M, Ishikawa H, Itokazu Y et al. Bone marrow stromal cells generate muscle cells and repair muscle degeneration. Science 2005;309:314–317.[Abstract/Free Full Text]

  58. von Melchner H., Housman DE. The expression of neomycin phosphotransferase in human promyelocytic leukemia cells (HL60) delays their differentiation. Oncogene 1988;2:137–140.[Medline]

  59. Valera A, Perales JC, Hatzoglou M et al. Expression of the neomycin-resistance (neo) gene induces alterations in gene expression and metabolism. Hum Gene Ther 1994;5:449–456.[Medline]

  60. Kohn DB, Weinberg KI, Nolta JA et al. Engraftment of gene-modified umbilical cord blood cells in neonates with adenosine deaminase deficiency. Nat Med 1995;1:1017–1023.[CrossRef][Medline]

  61. LaBarge MA, Blau HM. Biological progression from adult bone marrow to mononucleate muscle stem cell to multinucleate muscle fiber in response to injury. Cell 2002;111:589–601.[CrossRef][Medline]

  62. Seshi B, Kumar S, King D. Multilineage gene expression in human bone marrow stromal cells as evidenced by single-cell microarray analysis. Blood Cells Mol Dis 2003;31:268–285.[CrossRef][Medline]

  63. Seshi B, Kumar S, Sellers D. Human bone marrow stromal cell: Coexpression of markers specific for multiple mesenchymal cell lineages. Blood Cells Mol Dis 2000;26:234–246.[CrossRef][Medline]

  64. Camargo FD, Green R, Capetanaki Y et al. Single hematopoietic stem cells generate skeletal muscle through myeloid intermediates. Nat Med 2003;9:1520–1527.[CrossRef][Medline]

  65. Corbel SY, Lee A, Yi L et al. Contribution of hematopoietic stem cells to skeletal muscle. Nat Med 2003;9:1528–1532.[CrossRef][Medline]




This article has been cited by other articles:


Home page
 Stem CellsHome page
D. K. Arrell, N. J. Niederlander, R. S. Faustino, A. Behfar, and A. Terzic
Cardioinductive Network Guiding Stem Cell Differentiation Revealed by Proteomic Cartography of Tumor Necrosis Factor {alpha}-Primed Endodermal Secretome
Stem Cells, February 1, 2008; 26(2): 387 - 400.
[Abstract] [Full Text] [PDF]

Home page
 Stem CellsHome page
S. Aguilar, E. Nye, J. Chan, M. Loebinger, B. Spencer-Dene, N. Fisk, G. Stamp, D. Bonnet, and S. M. Janes
Murine but Not Human Mesenchymal Stem Cells Generate Osteosarcoma-Like Lesions in the Lung
Stem Cells, June 1, 2007; 25(6): 1586 - 1594.
[Abstract] [Full Text] [PDF]

Home page